Results 371 to 380 of about 1,992,684 (401)
Some of the next articles are maybe not open access.
Tumor heterogeneity and circulating tumor cells
Cancer Letters, 2016In patients with cancer, individualized treatment strategies are generally guided by an analysis of molecular biomarkers. However, genetic instability allows tumor cells to lose monoclonality and acquire genetic heterogeneity, an important characteristic of tumors, during disease progression.
Chufeng Zhang +4 more
openaire +3 more sources
Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers
Urologic Clinics of North America, 2023Liquid biopsies such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have great potential to serve as prognostic and predictive biomarkers in urologic cancers. The possibility of using liquid biopsies for real-time noninvasive and dynamic monitoring of response to therapy has been an active area of investigation.
Ikenna, Madueke +2 more
openaire +2 more sources
Circulating Tumor Cells Revisited
JAMA, 2010DESPITE THE USE OF MODERN HIGH-RESOLUTION imaging technologies, it is not possible to detect tumor cell metastasis at a single cell level. To date, cancer treatment is initiated only after the clinical presentation of disease. This approach generally is unsuccessful and translates into the dogma that metastasis is a terminal process, generally viewed ...
Massimo Cristofanilli, Stephan Braun
openaire +3 more sources
Circulating Tumor Cells in Mesenchymal Tumors [PDF]
, 2021 Circulating tumor cells (CTCs) play an important role in dissemination and metastases of mesenchymal tumors. Due to the rarity of these tumors and the absence of specific markers expressed by circulating mesenchymal tumor cells, the characterization of these cells is limited. Here, we provide an overview on the origin of mesenchymal tumor heterogeneity
José Gabriel RodrÃguez Tarazona +1 more
openaire +1 more source
2016
Breast cancer (BC) therapy has fundamentally progressed in the last 30 years with the change from radical mastectomy to recent individualized local and systemic therapy regimens. By combining the modern treatment modalities, approximately 77 % of BC patients can be cured, still leaving potential for optimization in 23 % of cases, which will develop ...
Malgorzata Banys-Paluchowski +3 more
openaire +4 more sources
Breast cancer (BC) therapy has fundamentally progressed in the last 30 years with the change from radical mastectomy to recent individualized local and systemic therapy regimens. By combining the modern treatment modalities, approximately 77 % of BC patients can be cured, still leaving potential for optimization in 23 % of cases, which will develop ...
Malgorzata Banys-Paluchowski +3 more
openaire +4 more sources
Automated genotyping of circulating tumor cells
Expert Review of Molecular Diagnostics, 2010Cancer remains a prominent health concern in modern societies. Continuous innovations and introduction of new technologies are essential to level or reduce current healthcare spending. A diagnostic platform to detect circulating tumor cells (CTCs) in peripheral blood may be most promising in this respect. CTCs have been proposed as a minimally invasive,
S. Hauch +10 more
openaire +4 more sources
Surgical Pathology Clinics, 2018
Circulating tumor cells (CTCs) are rare tumor cells found in the blood of patients with cancer that can be reliably detected by CTC technologies to provide prognostic, predictive, and diagnostic information. CTC sampling reflects intratumoral and intertumoral heterogeneity better than targeted biopsy.
openaire +2 more sources
Circulating tumor cells (CTCs) are rare tumor cells found in the blood of patients with cancer that can be reliably detected by CTC technologies to provide prognostic, predictive, and diagnostic information. CTC sampling reflects intratumoral and intertumoral heterogeneity better than targeted biopsy.
openaire +2 more sources
Circulating Tumor Cells and Tumor Dormancy
2016Metastatic cancer can recur months or even years after apparently successful treatment of the primary tumor. While the exact mechanisms leading to cancer recurrence remain poorly understood, failure to completely eliminate dormant micrometastases and solitary metastatic cells is believed to be a major contributor.
Ann F. Chambers, Alison L. Allan
openaire +2 more sources
Circulating tumor cells: the Grand Challenge
Lab on a Chip, 2011Jaap den Toonder, Lab on a Chip Editorial Board Member, discusses how the field of circulating tumour cells defines one of the Grand Challenges for the microfluidics community.
openaire +3 more sources
Current treatment and recent progress in gastric cancer
Ca-A Cancer Journal for Clinicians, 2021Smita S Joshi, Brian D Badgwell
exaly